KRAS and colorectal carcinoma: Ninty-four patients with pretreated KRAS G12C mutated metastatic CRC were given adagrasib 600 mg twice daily and cetuximab with an initial loading dose of 400 mg per square meter of body-surface area, followed by 250 mg per square meter every week or 500 mg per square meter every other week.